In the past week, BIOA stock has gone down by -1.13%, with a monthly gain of 11.42% and a quarterly plunge of -1.13%. The volatility ratio for the week is 1.86%, and the volatility levels for the last 30 days are 2.76% for BioAge Labs Inc The simple moving average for the past 20 days is 4.13% for BIOA’s stock, with a -51.89% simple moving average for the past 200 days.
Is It Worth Investing in BioAge Labs Inc (NASDAQ: BIOA) Right Now?
Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 1 as “sell.”
The public float for BIOA is 21.05M, and currently, short sellers hold a 7.52% ratio of that floaft. The average trading volume of BIOA on June 19, 2025 was 294.70K shares.
BIOA) stock’s latest price update
BioAge Labs Inc (NASDAQ: BIOA)’s stock price has soared by 0.92 in relation to previous closing price of 4.35. Nevertheless, the company has seen a loss of -1.13% in its stock price over the last five trading days. globenewswire.com reported 2025-06-17 that Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across multiple therapeutic indications EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the launch of an initiative to comprehensively profile and analyze samples from the HUNT Biobank in Norway.
Analysts’ Opinion of BIOA
Morgan Stanley, on the other hand, stated in their research note that they expect to see BIOA reach a price target of $5, previously predicting the price at $40. The rating they have provided for BIOA stocks is “Underweight” according to the report published on December 10th, 2024.
Jefferies gave a rating of “Hold” to BIOA, setting the target price at $7 in the report published on December 09th of the previous year.
BIOA Trading at 8.29% from the 50-Day Moving Average
After a stumble in the market that brought BIOA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.51% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIOA starting from Barton Shane, who purchase 2,632 shares at the price of $18.00 back on Sep 27 ’24. After this action, Barton Shane now owns 2,632 shares of BioAge Labs Inc, valued at $47,376 using the latest closing price.
Pande Vijay Satyanand, the Director of BioAge Labs Inc, purchase 126,793 shares at $19.73 during a trade that took place back on Oct 01 ’24, which means that Pande Vijay Satyanand is holding 1,026,793 shares at $2,501,626 based on the most recent closing price.
Stock Fundamentals for BIOA
Current profitability levels for the company are sitting at:
- -56.39 for the present operating margin
The net margin for BioAge Labs Inc stands at -48.96. The total capital return value is set at -0.26. Equity return is now at value -30.20, with -27.15 for asset returns.
Based on BioAge Labs Inc (BIOA), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -5.75. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -91.43.
Currently, EBITDA for the company is -78.19 million with net debt to EBITDA at 3.39. When we switch over and look at the enterprise to sales, we see a ratio of -62.61. The receivables turnover for the company is 4.02for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.68.
Conclusion
In a nutshell, BioAge Labs Inc (BIOA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
